Sympathomimetic syndrome caused by autointoxication with methylphenidate;Sympathicomimetisch syndroom door auto-intoxicatie met methylfenidaat

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 48, 2006, Pages 2661-2664

  Van Vulpen, L F D ^a   Malingre M M ^a   Lange, R ^a   Bartelink, A K M ^a  

^a MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; DRUG METABOLITE; ETHYLPHENIDATE; IBUPROFEN; LAXATIVE; METHYLPHENIDATE;

ADULT; AGITATION; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTOXICATION; HALLUCINATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LETHAL DOSE; MALE; MYDRIASIS; SINUS TACHYCARDIA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDOTES; CATHARTICS; CHARCOAL; HUMANS; IBUPROFEN; MALE; METHYLPHENIDATE; SUICIDE, ATTEMPTED; SYMPATHOMIMETICS; TREATMENT OUTCOME; WINE;

EID: 33845331330     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002;14:219-23.
2. Gorcum TF van, Velzen AG van, Riel AJHP van, Meulenbelt J, Vries I de. Acute vergiftigingen bij mens en diet. Jaarrapport 2004. Rapport 348802022. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu/Nationaal Vergiftigingen Informatie Centrum; 2005. p. 29.
3. Poisindex system. Greenwood Village: Thomson Micromedex; 2006.
4. Donker GA, Groenhof F, Veen WJ van der. Toenemend aantal voorschriften voor methylfenidaat in huisartspraktijken in Noordoost-Nederland, 1998-2003. Ned Tijdschr Geneeskd. 2005;149:1742-7.
5. White SR, Yadao CM. Characterization of methylphenidate exposures reported to a regional poison control center. Arch Pediatr Adolesc Med. 2000;154:1199-203.
6. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406-33.
7. Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate. A review of its locomotor effects. Brain Res Bull. 2006;68:393-405.
8. Lynton RC, Albertson TE. Amphetamines and design drugs. In: Dart RC, editor. Medical toxicology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1074-83.
9. IB1-tekst Ritalin. Den Haag: College ter beoordeling van geneesmiddelen; 2005.
10. Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, et al. Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol. Drug Metab Dispos. 2000;28:620-4.
11. Markowitz JS, Logan BK, Diamond F, Patrick KS. Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. J Clin Psychopharmacol. 1999;19:362-6.
12. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-8.
13. Langendijk PNJ, Wilde AAM. Medicatie voor aandachtstekort- hyperactiviteitstoornis (ADHD) en het risico op cardiovasculaire sterfte. Ned Tijdschr Geneeskd. 2006;150:1713-4.
14. Meulemans A, Dhondt E. Acute intoxicaties. In: Thijs LG, Delooz HH, Goris RJA, Sehers HJ, redacteuren. Acute geneeskunde: een probleemgerichte benadering in acute genees- en heelkundige situaties. 6e dr. Maarssen: Elsevier Gezondheidszorg; 2005. p. 297-309.
15. Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. Subst Abuse. 2002;23:165-9.
16. Bailey B, Letarte A, Abran MC. Methylphenidate unintentional ingestion in preschool children. Ther Drug Monit. 2005;27:284-6.